HALB.US Tykhe Corp

Healthcare Biotechnology USA Stocks
0.0017 USD
Close of Nov 14, 2026
0.0006 0.0020
Market cap
USD 1.20M
P/E
-
P/B
16.90x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jan 2026.

Is HALB.US undervalued?

Graham number

The Graham number of Tykhe Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Tykhe Corp fundamental analysis

No fundamental analysis for Tykhe Corp yet.

Tykhe Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Tykhe Corp

Halberd Corporation, a biotech company, develops treatments for blood-borne and neurologic diseases. It offers treatments for post-traumatic stress disorder/chronic traumatic encephalopathy, cancer, and COVID-19. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.

Full company profile